Alopecia Areata Clinical Trial
Official title:
Clinical Treatment of Alopecia Areata With Stem Cell Educator Therapy
Alopecia areata (AA) is a common autoimmune disease that results in loss of body hair in varying degrees. The condition is estimated to affect more than 6.8 million people in the United States alone (naaf.org), with a worldwide prevalence of 0.1% to 0.2% and calculated lifetime risk of 2%. AA is the most common form of the disease, in which areas of complete hair loss arise within normal hair-bearing skin. Other forms include alopecia totalis (AT), characterized by total loss of scalp hair, and alopecia universalis (AU), characterized by complete loss of body hair. AA and its variants can have devastating effects on patients' quality of life and social functioning. At present, curative therapy for AA does not exist. Therapeutic options are currently very limited, such as intralesional injections of glucocorticoids and induction of allergic contact dermatitis. These therapies are not effective for many patients and are generally impractical for patients with diffuse AA, AT or AU. Recently, Janus kinase (JAK) inhibitors were effective for the treatment of severe AA. However, for those patients who do respond, relapses are common after discontinuation of treatment, due to the existing of autoimmune memory T cells. Stem Cell Educator (SCE) therapy, which uses only autologous mononuclear cells that are externally exposed to cord blood stem cells, has previously been proven safe and effective in subjects for the improvement of type 1 diabetes (T1D), T2D and other autoimmune diseases such as alopecia areata. Minoxidil is the FDA approved drug for the treatment of androgenetic alopecia (AGA) in 1988. This trial will explore the therapeutic potential of Stem Cell Educator therapy for the treatment of AA by using topical minoxidil as control.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05051761 -
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
|
Phase 3 | |
| Active, not recruiting |
NCT03570749 -
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
|
Phase 2/Phase 3 | |
| Completed |
NCT02812342 -
Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants
|
Phase 2 | |
| Completed |
NCT02350023 -
Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata
|
Phase 4 | |
| Completed |
NCT02018042 -
An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata
|
Phase 2 | |
| Terminated |
NCT01898806 -
Intralesional Steroids in the Treatment of Alopecia Areata
|
Phase 4 | |
| Active, not recruiting |
NCT04517864 -
PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
|
Phase 2 | |
| Not yet recruiting |
NCT05803070 -
Topical Cetirizine in Treatment of Localized Alopecia Areata
|
||
| Not yet recruiting |
NCT05496426 -
A Study of KL130008 in Adults With Severe Alopecia Areata
|
Phase 2 | |
| Completed |
NCT04147845 -
Transepidermal Delivery of Triamcinolone Acetonide or Platelet Rich Plasma Using Either Fractional Carbon Dioxide Laser or Microneedling in Treatment of Alopecia Areata
|
N/A | |
| Terminated |
NCT03325296 -
Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.
|
Phase 2 | |
| Recruiting |
NCT05635266 -
A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Enrolling by invitation |
NCT05745389 -
CorEvitas Alopecia Areata (AA) Safety and Effectiveness Registry
|
||
| Recruiting |
NCT04246372 -
Tofacitinib for Immune Skin Conditions in Down Syndrome
|
Phase 2 | |
| Not yet recruiting |
NCT06087796 -
Topical Pentoxifylline; Metformin Versus Betamethasone in the Treatment of Alopecia Areata.
|
Phase 1 | |
| Withdrawn |
NCT03532958 -
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
|
Phase 2 | |
| Recruiting |
NCT02604888 -
Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females
|
N/A | |
| Terminated |
NCT01385839 -
Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata
|
N/A | |
| Completed |
NCT00408798 -
Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin
|
N/A | |
| Completed |
NCT00177021 -
Aldara for the Treatment of Extensive Alopecia Areata
|
Phase 4 |